Medscape weighs clinician conflicts over patient demand for retatrutide
The commentary frames the tension physicians face when patients seek the investigational triple agonist outside of Eli Lilly's clinical trials.
MH
By Maren Holt · Senior Reporter, GLP-1
Aug 19 03:00 ETSource: Medscape
The wire
- 01Medscape published a clinical commentary on retatrutide and the friction it creates between physicians and patients asking about the unapproved incretin.
- 02Retatrutide remains investigational, so clinicians are fielding requests for a drug they cannot legally prescribe outside trials.
- 03This is opinion rather than new data; no trial results or regulatory action accompany the piece.
From the source
Read at medscape.comRetatrutide: Pitting Physician Against Patient